Curis Management
Management criteria checks 3/4
Curis' CEO is Jim Dentzer, appointed in Sep 2018, has a tenure of 6.17 years. total yearly compensation is $1.66M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 0.072% of the company’s shares, worth $25.01K. The average tenure of the management team and the board of directors is 5.3 years and 10.3 years respectively.
Key information
Jim Dentzer
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 38.1% |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.07% |
| Management average tenure | 5.3yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Nov 14
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Sep 16Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study
Aug 18Curis: Asymmetric Risk And Reward
Jul 17Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation
Mar 28Checking In On Curis
Dec 15Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth
Dec 04We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth
Aug 29Curis Inc.: Revisiting CA-4948 After Q2 Update
Aug 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$2m | US$634k | -US$47m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$3m | US$615k | -US$57m |
| Sep 30 2022 | n/a | n/a | -US$59m |
| Jun 30 2022 | n/a | n/a | -US$57m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$3m | US$590k | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$545k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$31m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$510k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | n/a | n/a | -US$30m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$2m | US$479k | -US$33m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$43m |
| Mar 31 2018 | n/a | n/a | -US$48m |
| Dec 31 2017 | US$2m | US$443k | -US$53m |
Compensation vs Market: Jim's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Dentzer (57 yo)
6.2yrs
Tenure
US$1,662,978
Compensation
Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$1.66m | 0.072% $ 25.0k | |
| CFO and Principal Financial & Accounting Officer | 2.3yrs | US$1.01m | 0.0076% $ 2.6k | |
| Chief Development Officer | 1.5yrs | US$1.04m | 0% $ 0 | |
| Vice President of Technology Management & Intellectual Property | 16.2yrs | US$413.39k | no data | |
| Chief Scientific Officer | no data | US$1.17m | no data | |
| VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Clinical Development | 5.3yrs | no data | no data |
5.3yrs
Average Tenure
59yo
Average Age
Experienced Management: CRIS's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$1.66m | 0.072% $ 25.0k | |
| Independent Chairman of the Board | 24.8yrs | US$158.70k | 0.015% $ 5.4k | |
| Independent Director | 14.4yrs | US$123.70k | 0.017% $ 5.9k | |
| Independent Director | 21yrs | US$126.20k | 0.017% $ 5.8k | |
| Independent Director | 2.9yrs | US$106.20k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$103.70k | 0% $ 0 |
10.3yrs
Average Tenure
66.5yo
Average Age
Experienced Board: CRIS's board of directors are seasoned and experienced ( 10.3 years average tenure).